IL17A and inflammatory skin disease: Apremilast, a PDE4 inhibitor, works by reducing the production of pro-inflammatory cytokines, including TNF-α, IL-17 and IL-23, which are involved in various inflammatory skin diseases.10 Its efficacy in this case is noteworthy, as the patient achieved complete remission without significant adverse effects.